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Abstract
Background: The cardinal symptoms of auto-immune myasthenia gravis are fatigue and weakness. Endurance
events such as marathon running would seem incompatible with this chronic disease. Many patients stop sport
altogether. There is limited literature of patients with auto-immune myasthenia gravis undergoing regular endurance
exercise.
Case presentation: We report the case of a 36-year-old female who began long-distance running whilst experiencing
initial symptoms of myasthenia gravis. She was diagnosed with auto-immune myasthenia gravis and whilst advised to
stop all sport, her way of fighting and living with this chronic and unpredictable disease was to continue running to
maintain a healthy body and mind. Despite suffering from ocular, bulbar and localized limb fatigability, she managed
to complete multiple marathons and achieve disease stability with cholinesterase inhibitors.
Conclusions: Marathon and half-marathon running lead to distinct changes in mediators of inflammation in an
exercise-dose-dependent manner. Despite symptoms of weakness and fatigue in certain muscles in myasthenia
gravis, physical exertion remains possible and may not worsen symptoms as demonstrated in this case and recent
studies. The immunomodulatory role of exercise could be considered in this case however this hypothesis remains to
be confirmed in future studies with quantitative data.
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Background
Auto-immune myasthenia gravis (MG) is a chronic dis-
ease whereby dysfunction at the neuromuscular junction
causes symptoms of fatigue and weakness [1]. Endurance
events such as marathon running would seem incompat-
ible with MG. Many patients stop sport altogether, find-
ing activities of daily living to be challenging enough in
themselves [2]. Even for the general public, marathon
running is not practiced by a large majority, one must
train regularly and have a high endurance capacity.
There are only three case studies combining sport and
MG reported in the literature. Scheer et al. (2012) de-
scribe a 52 year old ultra-endurance athlete with mild
MG (MGFA IIa), treated with 10 mg of prednisone who
completed a 220 km ultra-marathon over 5 days [3].
Fatigue, leg weakness, dysphagia and breathing problems
were reported, relieved by rest, shade and 60 mg of pyri-
dostigmine every 90 min (max daily dose 720 mg). He
began running 5 years prior to MG diagnosis and main-
tained a combined weekly running distance of 70 km.
Stout et al. (2001) report a 26 year old athletic (baseball
and weight lifting) student who suffered from extreme
weakness and atrophy due to his MG, he was unable to
do a single push-up at diagnosis [4]. Once stabilized he
began exercising again at low levels which prevented fur-
ther weakness but he struggled to regain force until
undergoing a 15-wk upper and lower limb resistance
training program, with oral creatine supplementation
and he was able to make force gains (37% leg extension)
and increase training volume (34–40% upper limb). Fi-
nally, Leddy et al. (2000) describe a 17 year old college
football player with mild generalized MG (antibody-ne-
gative, 15% decrement RNS-EMG), treated with 60 mg
prednisone every other day and 60 mg pyridostigmine
q.i.d [5]. Following an initial period of weakness at the
time of diagnosis, his strength returned to normal after
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6 weeks and aside from a relapse associated with a
period of non-compliance with medication, he became
stable without treatment and was able to participate in
full football practice.
Three recent uncontrolled trials have demonstrated
benefits and tolerance of supervised physical activity (re-
sistance or aerobic) programs for patients with stable
MG [6–8]. Additionally, using the contralateral limb as a
control, Lohi et al. found improvements in lower limb
force following dynamic training and no deterioration
nor negative side effects in a group of 11 subjects with
mild MG [9]. A review article has suggested that risk
factors for exacerbation of MG include prolonged exer-
cise, running uphill and activity with stairs, however no
specific data was provided to support these claims [10].
Currently there are no official guidelines regarding par-
ticipation in sport and MG [11, 12].
Case presentation
Here we report a 36-year-old female nurse, working
full-time 12-h night shifts in a busy intensive care service,
with generalized (MGFA IIb) auto-immune MG, symp-
tomatic and dependent on cholinesterase inhibitors. Past
medical history includes eczema in her teens, she is a car-
rier for sickle disease (sickle cell trait (SCT)) and she car-
ried two pregnancies to term. Red blood cells have slightly
reduced mean corpuscular volume and mean corpuscular
hemoglobin concentration, 75.5 fl and 25.7 pg, respect-
ively. She has no clinical symptoms of anemia and no spe-
cific treatment or monitoring. Surgical history includes 1
cesarean (2004), linea alba repair (2011) and breast im-
plant (2014). She is a nonsmoker and does not drink
alcohol. She is right-handed. She has a normal body mass
index, 20.3 kg/m2, weighing 52 kg for 1.60 m.
Despite already experiencing abnormal weakness, she
began running a year before being diagnosed with MG.
Prior to running, she played amateur level basketball
however this became incompatible with working
night-shifts. MG diagnosis was based on clinical signs
(right hand weakness - difficulty brushing teeth and hair,
carrying light loads, cutting meat, a heavy head, nasal
voice, ptosis, diplopia, dysphagia and difficulty masticat-
ing and articulating), serum auto-antibodies against nic-
otinic acetylcholine receptors (AChR) (> 100 nmol/l) and
significant decrement on repetitive nerve stimulation
(3 Hz) EMG (50% right trapezius, 24% right anconeus,
15% left anconeus, 43% tongue/mouth (CN V/XII)). My-
asthenic muscle score (MMS) was 65/100. Initial treat-
ment consisted of intravenous immunoglobulins (2 g/kg
over 3 days (100 g)) and 60 mg pyridostigmine (t.i.d).
Thoracic CT scan did not show thymoma but was in
favour of thymic hyperplasia. Thymectomy was not per-
formed as per the patient’s request.
Despite the patient being informed at diagnosis that
sport was contra-indicated, she kept running. Training
consisted of 1–2 10 km weekly runs with the beginning
being the most difficult. MG symptoms persisted includ-
ing fatigue, dysphagia and episodes of diplopia at the
end of pyridostigmine dose thus aziathoprine (100 mg)
was introduced. She performed a half marathon
2 months later, followed by a full marathon and another
half marathon. No major difficulty was experienced and
performances significantly improved: 5h13mins (8.1 km/
h) for a marathon pre-diagnosis to 4h51mins (8.7 km/h)
post diagnosis (and treatment), Figs. 1 & 2.
Fig. 1 Running performance timeline
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On clinical evaluation 1 year after MG diagnosis, she
had above average respiratory strength (MIP and MEP
135% and 144% of theoretical) and normal respiratory
function (FVC 95% of theoretical). On maximal volun-
tary testing, limb strength was normal (knee extensors
and elbow flexors: 128% and 101% of theoretical, re-
spectively and right handgrip strength: 88%). Walking
endurance was also considered normal (92% of theoret-
ical 6MWD). The MMS suffered from a ceiling effect
with the patient achieving the maximal score of 100 and
a score of 4 on the MG-ADL due to episodes of dyspha-
gia, dyspnea with effort and UL fatigue with brushing
her teeth and hair. She reported recurrent MG symp-
toms including loss of hand dexterity (difficulty manipu-
lating medication at work), bulbar symptoms such as
dysphagia on her own saliva, a nasal voice and ocular
symptoms (ptosis and diplopia). MG-specific quality of
life (MGQOL-15-F) was reduced (17/60) particularly
with regards to professional and social aspects, reflected
in the WHO-QOL Bref with the social relationship and
physical health domains being reduced, 11/20 and 13/20
respectively [13, 14].
She continued regular running without any particular
changes in her MG, recurrent right hand weakness per-
sisted and she experienced occasional ocular and bulbar
symptoms primarily at the end of pyrodistigmine dose.
Quality of life improved significantly over time (Fig. 2)
and strength remained stable (knee extensors and elbow
flexors: 128% and 100% of theoretical, respectively, right
handgrip strength: 93%). She discontinued aziathoprine
(treatment duration 14 months) and remained exclu-
sively treated with cholinesterase inhibitors (60 mg,
b.i.d).
Discussion and conclusion
It is well known that MG does not affect all muscles to
the same extent and whilst some muscles may clearly be
affected, other muscles may function normally and can be
trained without adverse effects. Thus, continuing activities
and daily life seems important for maintaining “un-
affected” muscles and for psychological benefits. With
regards to physical activity a close link between endurance
running and the immune system activity has been demon-
strated [15]. During sustained physical activity, repeated
muscle contractions stimulate the production of inflam-
matory cytokines such as Interleukin-6 (IL-6) by myo-
cytes. IL-6 may act as an inhibitor to pro-inflammatory
cytokines such as TNF-α which is a potent mediator of tis-
sue damage [16, 17]. IL-6 also stimulates the production
of IL-10 (an anti-inflammatory cytokine) and IL-1ra, gen-
erating an anti-inflammatory environment. Whether these
effects can modify disease activity in MG currently re-
mains unclear. These exercise-induced mediators of in-
flammation are susceptible to exercise dose, with greater
increases seen following a marathon as compared to a half
marathon, for example [16]. A disease-specific response
has been suggested for the change in cytokine kinetics in
relation to exercise [18].
Fig. 2 Diagnosis, clinical evaluation and running timeline
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Whilst evidence of exercise-induced change of cytokines
remains sparse in MG, there is growing evidence of the
presence of inflammation and modulation of the immune
response by cytokines in MG pathogenesis [19, 20]. Cer-
tain cytokines are upregulated (IL-17, IL-21, IL-6, IL-10)
and others downregulated (IL-4) compared to control
subjects [19, 21–23]. A recent study evaluated serum IL-6
before and after a twice-weekly, 3 month training program
in subjects with ocular or mild, generalized MG. Serum
Il-6 levels remained unchanged [7]. However, circulating
microRNAs (miR150-5p and miR21-5p) decreased [7].
These immuno-microRNAs have been suggested as new
biomarkers in AChR MG, notably miR150-5p as a marker
for disease severity [24, 25].
Another factor which warrants consideration here is
the localized role of IL-6 in triggering satellite cells in
the myogenic process [26]. Whilst research has demon-
strated the role of IL-6 in muscle atrophy, this has pre-
dominantly involved pathological situations such as
cancer cachexia and ageing [27] where there is chronic
inflammation. When released at low concentration into
satellite cell niches IL-6 could promote repair and regen-
erate skeletal muscle tissue [27]. It seems that IL-6 is
deregulated in the muscles of MG patients, possibly due
to AChR antibodies deregulating the IL-6 pathway [28].
In the case of this patient, weakness induced by MG
mechanisms tends to affect the same muscles which were
initially affected, regardless of increased exertion. Whether
this patient has benefitted from protective effects of exer-
cise or not is difficult to determine, however, this case
study demonstrates that an endurance sport such as run-
ning marathons and MG are not mutually exclusive. The
immunosuppressor treatment likely played an essential
role in attenuating the autoimmune attack enabling the
patient to improve and optimize her physical capacities.
Clinical scores improved and remained stable and running
performance improved and remained relatively consistent
(Figs. 1 and 2). The level of antibodies against AChR de-
creased over time (Fig. 2) however this also coincided with
immunosuppressor treatment.
In stabilized MG there are no clear arguments to fear
adverse effects of physical activity and as well as positive
psychological effects, patients will benefit from cardio-
vascular and muscular adaptions as well as possible im-
munomodulatory effects. It is important to consider
each individual case and weigh up the benefits and risks
and possibly put into place a supervised or specific return
to sport program where necessary. As can be expected in
the absence of disease, inter-individual variation is likely
with strenuous physical exercise.
It seems important to discuss the possible conse-
quences of exercise and sickle cell trait which are not
currently clear in the literature. Case-control studies
have found an increased prevalence of sudden death on
exertion, often called “exercise collapse associated with
sickle trait” however a direct causal relationship has not
been confirmed [29]. It has been suggested that a com-
bination of factors [30] such as high altitude or severe
dehydration combined with intense physical activity
could cause red blood cells to become deformed or sick-
led and cause complications such as rhabdomyolysis.
This may be due to lower capillary density and tortuos-
ity, reduced small vessels and a higher percentage of
broader micro vessels [31]. Microvascular remodeling
may be a compensatory mechanism to facilitate normal
blood flow [29] which may be present in this patient
considering the raised but not excessive elevation of CK
following a marathon (data not presented). SCT may not
be a completely benign carrier state nor a true disease
entity but rather a potential risk factor which could be
monitored. Maintaining physical fitness may be a pro-
tective agent by decreasing the endothelial activation
through improvements in nitric oxide and antioxidant
availability [32, 33]. Precautions would be the same as
for exercise with MG i.e.; adequate hydration, control
heat exposure and monitor exertion intensity [34].
This case report demonstrates that despite being in the
first 2 years of MG disease onset in which exacerbations
and instability are most common, and despite regular in-
tense endurance running, the MG has remained stable. A
growing body of literature suggests that regular physical
exercise may lead to anti-inflammatory effects in chronic
auto-immune diseases. The immunomodulatory role of
exercise could be considered in this case study. However,
further studies regarding the specific effects of exercise on
disease activity in MG are necessary to confirm these
speculations.
Patient perspective
“I am myasthenic and marathonian, running allows me
to take time for myself, to evacuate stress and to think.
It’s a real therapy”.
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